Antibodies to Heterologous Proteins in Hemophilia A Patients Receiving Recombinant Factor VIII (Recombinate™)

Jørgen Ingerslev; Kirsten Christiansen; Hanne B. Ravn; Gordon L. Bray; Edward D. Gomperts; The Recombinate Study Group

doi:10.1055/s-0037-1613059

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2002; 87(04): 626-634
DOI: 10.1055/s-0037-1613059

Review Article

Schattauer GmbH

Antibodies to Heterologous Proteins in Hemophilia A Patients Receiving Recombinant Factor VIII (Recombinate™)

Authors

Jørgen Ingerslev

¹Center for Hemophilia and Thrombosis, Department of Clinical Immunology, University Hospital Skejby, Aarhus, Denmark
Kirsten Christiansen

¹Center for Hemophilia and Thrombosis, Department of Clinical Immunology, University Hospital Skejby, Aarhus, Denmark
Hanne B. Ravn

¹Center for Hemophilia and Thrombosis, Department of Clinical Immunology, University Hospital Skejby, Aarhus, Denmark
Gordon L. Bray

²Baxter BioScience, Glendale, California, USA
Edward D. Gomperts

²Baxter BioScience, Glendale, California, USA

The Recombinate Study Group

Abstract

Summary

As a consequence of the manufacturing process, trace quantities of Chinese hamster ovary cell protein, bovine serum albumin and murine immunoglobulin G are present in Recombinate™ recombinant human factor VIII (rhFVIII). The development of antibodies (Abs) to these heterologous proteins was evaluated during long-term rhFVIII therapy of hemophilia A in 68 previously treated and 73 previously untreated patients. Ab prevalence was also assessed in 157 non-hemophilic subjects. Abs against heterologous proteins could be detected in varying percentages of patients and non-hemophilic subjects. Abs arose in patients sporadically, and levels were typically low. There were no adverse events associated with development or presence of anti-heterologous protein Abs. These data indicate that sustained immune responses to trace levels of heterologous proteins are very infrequent during long-term rhFVIII therapy.

Keywords

Factor VIII - recombinant proteins - CHO cells - antibodies - monoclonal - serum albumin - bovine

Full Text

References

References
1 Bray GL, Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-Johnson M, Shapiro A, Scheibel E, White II G, Lee M. The Recombinate Study. A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. Blood 1994; 83: 2428-35.
2 Scharrer I, Bray GL, Neutzling O. Incidence of inhibitors in haemophilia A patients-a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 1999; 05: 145-54.
3 White II GC, McMillan CW, Kingdon HS, Shoemaker CB. Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia. N Engl J Med 1989; 320: 166-70.
4 Bray GL. The Recombinate Study Group. Current status of clinical studies of recombinant factor VIII (Recombinate) in patients with hemophilia A. Transfus Med Rev 1992; 06: 252-5.
5 Morfini M, Longo G, Messori A, Lee M, White G, Mannucci P. The Recombinate Study Group. Pharmacokinetic properties of recombinant factor VIII compared with a monoclonally purified concentrate (Hemofil M). Thromb Haemost 1992; 68: 433-5.
6 Gomperts E. Recombinate study. Ann Hematol 1994; 68: S51.
7 White II GC. Summary of clinical experience with recombinant factor VIII products-Recombinate. Ann Hematol 1994; 68 (03) S7-S8.
8 Kelly KM, Butler RB, Farace L, Cohen AR, Manno CS. Superior in vivo response of recombinant factor VIII concentrate in children with hemohilia A. J Pediatr 1997; 130: 537-40.
9 White II GC, Courter S, Bray GL, Lee M, Gomperts ED. The Recombinate Previously Treated Patient Study Group. A multicenter study of recombinant factor VIII (Recombinate™) in previously treated patients with hemophilia A. Thromb Haemost 1997; 77: 660-7.
10 Parti R, Ardosa J, Yang L, Mankarious S. In vitro stability of recombinant human factor VIII (Recombinate™). Haemophilia 2000; 06: 513-22.
11 Lawrence J. Recombinate: viral safety and final product manufacturing testing and specifications. Ann Hematol 1994; 68 (03) S21-S24.
12 Davis HM, Brown SK, Nash DW, Pennetti AM, Salzman PM, Schreiber AB, Haimovich J. Lack of immune response to mouse IgG in hemophilia A patients treated chronically with Monoclate®, a monoclonal antibody affinity purified factor VIII preparation. Thromb Haemost 1990; 63: 386-91.
13 Griffith M. Ultrapure plasma factor VIII produced by anti-F VIII c immunoaffinity chromatography and solvent/detergent viral inactivation. Characterization of the Method M process and Hemofil M antihemophilic factor (human). Ann Hematol 1991; 63: 131-7.
14 Brackmann HH, Gomperts ED, Courter SC, Vidor A, O’Brein S, Oldenburg J. Long-term surveillance for human anti-murine antibodies of a group of haemophiliacs treated only with immunoaffinity-purified factor VIII concentrates. Haemophilia 1995; 01: 111-4.
15 Davis HM, Nash DW, Clymer MD, Frigo ML, Bergman GE. Lack of immune response to mouse IgG in previously untreated haemophilia A and haemophilia B patients treated with monoclonal antibody purified factor VIII and factor IX preparations. Haemophilia 1997; 03: 102-7.
16 Guerci AD, Gerstenblith G, Brinker JA, Chandra NC, Gottlieb SO, Bahr RD, Weiss JL, Shapiro EP, Flaherty JT, Bush DE. A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty. N Engl J Med 1987; 317: 1613-8.
17 Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer III FE, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH. The Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-94.
18 Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME. The Pulmozyme Study Group. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994; 331: 637-42.
19 Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998; 58: 2825-31.
20 Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 1997; 90: 2188-2195.
21 Brettler DB, Forsberg AD, Levine PH, Petillo J, Lamon K, Sullivan JL. Factor VIII:C concentrate purified from plasma using monoclonal antibodies: human studies. Blood 1989; 73: 1859-63.
22 Haimovich J, Davis HM, Schreiber AB. Human anti-mouse immunoglobulins in sera of patients treated chronically with monoclonal antibodypurified factor VIII. Semin Hematol 1990; 27: 11-5.
23 Addiego Jr JE, Gomperts E, Liu SL, Bailey P, Courter SG, Lee ML, Neslund GG, Kingdon HS, Griffith MJ. Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIIIc immunoaffinity chromatography. Thromb Haemost 1992; 67: 19-27.
24 Axelrod HR, Liao MJ, Kuchler M, Testa D. Trace amounts of murine immunoglobulin in affinity purified leukocyte interferon alpha are not immunogenic. Biotechnol Ther 1992; 03: 35-49.
25 Nicolaisen EM, Hansen LL, Poulsen F, Glazer S, Hedner U. Immunological aspects of recombinant factor VIIa (rFVIIa) in clinical use. Thromb Haemost 1996; 76: 200-4.
26 Seremetis S, Lusher JM, Abildgaard CF, Kasper CK, Allred R, Hurst D. Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy. The KOGENATE Study Group. Haemophilia 1999; 05: 9-16.
27 Evans RS, Pestotnik SL, Classen DC, Horn SD, Bass SB, Burke JP. Preventing adverse drug events in hospitalised patients. Ann Pharmacother 1994; 28: 523-7.